Trial Profile
An Open-label Study to Evaluate the Safety of Multiple Doses of Denosumab 120mg Administered Subcutaneously in Subjects With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Hypocalcaemia
- Focus Adverse reactions
- Sponsors Amgen
- 22 Sep 2014 New trial record